These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 15903292)

  • 1. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
    Grinspoon SK
    Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.
    Barbaro G
    Curr Pharm Des; 2007; 13(21):2208-13. PubMed ID: 17627554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.
    Shikuma CM; Day LJ; Gerschenson M
    Curr Drug Targets Infect Disord; 2005 Sep; 5(3):255-62. PubMed ID: 16181144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome associated with HIV and highly active antiretroviral therapy.
    Barbaro G; Iacobellis G
    Curr Diab Rep; 2009 Feb; 9(1):37-42. PubMed ID: 19192423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection.
    Tanwani LK; Mokshagundam SL
    South Med J; 2003 Feb; 96(2):180-8; quiz 189. PubMed ID: 12630645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.
    Chen D; Misra A; Garg A
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4845-56. PubMed ID: 12414837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?
    Behrens GM; Stoll M; Schmidt RE
    Drug Saf; 2000 Jul; 23(1):57-76. PubMed ID: 10915032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV and increased risk of cardiovascular diseases.
    Das S
    Sex Health; 2005; 2(4):219-21. PubMed ID: 16402668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV infection, highly active antiretroviral therapy and the cardiovascular system.
    Barbaro G
    Cardiovasc Res; 2003 Oct; 60(1):87-95. PubMed ID: 14522410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metabolic and cardiovascular effects of combined antiretroviral therapy in patients with HIV infection. Systematic review of literature].
    Casaretti L; Paolillo S; Formisano R; Bologna A; Mattiello G; Conte S; Petraglia L; Lo ludice F; Fabiani I; Cirillo AP; Vitagliano A; Gambardella F; della Ratta GL; Filardi PP
    Monaldi Arch Chest Dis; 2011 Dec; 76(4):175-82. PubMed ID: 22567733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk.
    Barbaro G; Barbarini G
    Chemotherapy; 2006; 52(4):161-5. PubMed ID: 16675900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome.
    Iacobellis G; Sharma AM; Pellicelli AM; Grisorio B; Barbarini G; Barbaro G
    Curr HIV Res; 2007 Mar; 5(2):275-9. PubMed ID: 17346142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic complications associated with antiretroviral therapy.
    Jain RG; Furfine ES; Pedneault L; White AJ; Lenhard JM
    Antiviral Res; 2001 Sep; 51(3):151-77. PubMed ID: 11448728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metabolic alterations in HIV-associated lipodystrophy syndrome].
    Valente AM; Reis AF; Machado DM; Succi RC; Chacra AR
    Arq Bras Endocrinol Metabol; 2005 Dec; 49(6):871-81. PubMed ID: 16544008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Disorders of lipid and glucose metabolism. Long-term adverse effects of antiretroviral therapy].
    Landauer N; Goebel FD
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():16-8. PubMed ID: 12043065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART.
    Cahn P; Leite O; Rosales A; Cabello R; Alvarez CA; Seas C; Carcamo C; Cure-Bolt N; L'Italien GP; Mantilla P; Deibis L; Zala C; Suffert T
    Braz J Infect Dis; 2010; 14(2):158-66. PubMed ID: 20563442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardiovascular risk factors associated with antiretroviral therapy].
    Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.